Sensei Biotherapeutics (NASDAQ:FTH) Shares Gap Up – What’s Next?

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) gapped up prior to trading on Friday. The stock had previously closed at $20.00, but opened at $21.00. Sensei Biotherapeutics shares last traded at $19.3890, with a volume of 10,288 shares.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Guggenheim assumed coverage on shares of Sensei Biotherapeutics in a report on Wednesday, September 16th. They issued a “buy” rating and a $70.00 target price for the company. BTIG Research restated a “buy” rating and set a $55.00 price objective on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, September 14th. Needham & Company LLC started coverage on shares of Sensei Biotherapeutics in a research report on Friday, August 21st. They set a “buy” rating and a $56.00 target price for the company. Finally, JonesTrading initiated coverage on shares of Sensei Biotherapeutics in a report on Tuesday, August 4th. They set a “buy” rating and a $55.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Sensei Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.25.

Sensei Biotherapeutics Trading Down 5.6%

The stock has a market capitalization of $502.43 million, a PE ratio of -0.14 and a beta of -0.29. The firm’s fifty day moving average price is $31.50.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating the consensus estimate of ($5.04) by $2.20. On average, sell-side analysts expect that Sensei Biotherapeutics, Inc. will post -13.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of FTH. Citadel Advisors LLC acquired a new stake in shares of Sensei Biotherapeutics in the second quarter valued at approximately $307,000. Renaissance Technologies LLC raised its stake in Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after acquiring an additional 20,525 shares in the last quarter. Bank of America Corp DE boosted its holdings in Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares in the last quarter. Stempoint Capital LP bought a new stake in Sensei Biotherapeutics in the first quarter worth approximately $4,188,000. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of Sensei Biotherapeutics in the second quarter worth $3,610,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.